Multibagger Pharma Stock Guides Rs 1,000 Crore Revenue Target For Next 3 Years; FII & DII Stake Increase, Q4 Total Income Jumps 13.50% YoY

On Wednesday, the Indian equity benchmarks ended marginally lower, with the benchmark Nifty 50 index declining 0.03 per cent to close at 23,907.15. Pharmaceutical stocks remained in focus amid quarterly earnings announcements and business expansion updates. In this segment, Lincoln Pharmaceuticals share price ended 1.43 per cent higher at Rs 758.15 on May 27, 2026, compared with the previous close of Rs 747.45.

Lincoln Pharmaceuticals reports FY26 earnings

Lincoln Pharmaceuticals Limited reported consolidated total income of Rs 704.48 crore for FY26, compared with Rs 645.71 crore in FY25, registering year-on-year growth of 9.10 per cent. EBITDA for FY26 stood at Rs 131.14 crore compared with Rs 123.97 crore in the previous financial year, reflecting growth of 5.78 per cent.

Profit before Tax increased to Rs 115.63 crore from Rs 109.19 crore in FY25, while net profit rose 6.74 per cent to Rs 87.89 crore from Rs 82.35 crore in the previous year. Earnings per share for FY26 stood at Rs 43.88 compared with Rs 41.11 in FY25.

The company recommended a Dividend of 18 per cent, equivalent to Rs 1.80 per equity share of face value Rs 10 each, for FY26.

Lincoln Pharmaceuticals Q4FY26 performance

For Q4FY26, consolidated total income increased 13.50 per cent to Rs 183.08 crore from Rs 161.30 crore in the corresponding quarter previous year. EBITDA for the quarter stood at Rs 20.66 crore compared with Rs 19.84 crore in Q4FY25, reflecting growth of 4.14 per cent.

Profit before tax rose to Rs 16.70 crore from Rs 16.25 crore in the year-ago quarter, while net profit stood at Rs 11.63 crore compared with Rs 11.57 crore in Q4FY25. Earnings per share for the quarter came in at Rs 5.81. The company stated that Q4FY26 financial performance was impacted due to war and global developments.

Growth targets and global expansion

Lincoln Pharmaceuticals said it is targeting revenue of Rs 1,000 crore within the next three years, supported by expansion into high-value product categories and entry into new markets.

The company aims to achieve annual growth of 15-18 per cent driven by strong performance across cardiac, diabetic, dermatology and ENT segments.

The company currently exports to more than 60 countries and plans to expand its international footprint to around 90 countries over the next two to three years. It recently entered the Canadian market and also received approvals from TGA Australia and EU GMP.

Management commentary

Commenting on the financial performance, Munjal Patel, Director, Lincoln Pharmaceuticals Ltd, said, “We are pleased to conclude FY26 on a strong note with healthy growth momentum driven by robust demand, improved operational efficiencies and consistent execution across markets. We remain focused on strengthening our product portfolio, expanding our domestic and international presence and investing in research and manufacturing capabilities. Backed by a debt-free balance sheet and strong fundamentals, we remain confident of sustaining profitable growth and creating long-term value for stakeholders.”

Shareholding and stock performance

Lincoln Pharmaceuticals Ltd traded at Rs 758.15 on May 27, 2026, at 3:44 PM, compared with the previous close of Rs 747.45, reflecting a gain of 1.43 per cent during the session.

Foreign institutional investor holding increased to 5.20 per cent as of March 31, 2026, compared with 5 per cent a year earlier, while domestic institutional investor holding stood at 1.08 per cent. Greenx Wealth Multihorizons Opportunity Fund held 1.07 per cent stake, while Rimo Capital Fund LP held 1.33 per cent stake in the company.

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Ltd is an Ahmedabad-based pharmaceutical company engaged in development and manufacturing of formulations across multiple therapeutic segments including anti-infective, respiratory, cardio, CNS, anti-diabetic and gynaecology products.

The company operates manufacturing facilities in Gujarat certified under international quality standards and exports pharmaceutical products to more than 60 countries globally.

What are your views on Lincoln Pharmaceuticals’ FY26 performance and expansion plans? Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.